What is HC Wainwright’s Forecast for Geron Q3 Earnings?

Geron Co. (NASDAQ:GERN) – Equities research analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Geron in a research report issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will earn ($0.09) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Geron’s FY2024 earnings at ($0.36) EPS and FY2025 earnings at ($0.23) EPS.

GERN has been the topic of a number of other reports. Scotiabank started coverage on Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Geron in a research report on Thursday, August 8th. StockNews.com upgraded shares of Geron to a “sell” rating in a research note on Monday, August 5th. Leerink Partners began coverage on shares of Geron in a research report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price for the company. Finally, Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.05.

Geron Stock Up 1.2 %

Shares of Geron stock opened at $4.27 on Wednesday. The company has a quick ratio of 3.60, a current ratio of 3.61 and a debt-to-equity ratio of 0.12. Geron has a twelve month low of $1.64 and a twelve month high of $5.34. The company has a market cap of $2.57 billion, a price-to-earnings ratio of -11.86 and a beta of 0.52. The company’s 50 day moving average is $4.33 and its 200 day moving average is $4.30.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Geron had a negative net margin of 15,990.68% and a negative return on equity of 73.79%. The firm had revenue of $0.88 million for the quarter, compared to the consensus estimate of $0.34 million. During the same quarter last year, the firm posted ($0.09) EPS. The business’s quarterly revenue was up 2941.4% compared to the same quarter last year.

Hedge Funds Weigh In On Geron

Several large investors have recently made changes to their positions in GERN. Darwin Global Management Ltd. bought a new position in shares of Geron during the second quarter worth $106,185,000. Tokio Marine Asset Management Co. Ltd. bought a new position in shares of Geron during the 1st quarter valued at about $333,000. Renaissance Technologies LLC purchased a new position in shares of Geron during the second quarter valued at about $3,315,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Geron by 999.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock worth $6,815,000 after purchasing an additional 1,877,184 shares during the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Geron in the second quarter worth about $539,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.